Caroline Robert
0000-0002-9493-0238
Publication & Citation Trends
Publications
0 total
Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Cited by 0
Semantic Scholar
The KEYNOTE-630 Trial: A Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC)
Cited by 1
Semantic Scholar
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database.
Cited by 7
Semantic Scholar
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
Cited by 0
Semantic Scholar
1051P Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial OA
Cited by 4
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(533)
Melanoma and MAPK Pathways
(518)
CAR-T cell therapy research
(389)
Cutaneous Melanoma Detection and Management
(309)
Immunotherapy and Immune Responses
(245)
Affiliations
Université Claude Bernard Lyon 1
Université Paris-Sud
Rutgers, The State University of New Jersey
AstraZeneca (United Kingdom)
Goethe University Frankfurt